Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Breast Cancer


 FAC                                                 breast(25,26)
 _________________________________________________________________
  fluorouracil.... 500 mg/sqm IV days 1 and 8.
  adriamycin...... 50 mg/sqm IV day 1.
  cytoxan......... 500 mg/sqm IV day 1.
  FREQUENCY....... Repeat cycle every 21 days.

   25. Blumenschein G, et.al. FAC chemotherapy for breast cancer. 
       Proc Am Soc Clin Oncol 15:193, 1974.

  reference...
    Hortobagyi GN.  Gutterman JU.  Blumenschein GR.  Tashima CK. 
    Burgess MA.  Einhorn L.  Buzdar AU.  Richman SP.  Hersh EM. 
    Combination chemoimmunotherapy of metastatic breast cancer 
    with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. 
    Cancer.  43(4):1225-33, 1979 Apr. 
  abstract...
    One hundred and five patients with metastatic breast cancer 
    were treated with 5-fluorouracil, Adriamycin, cyclophosphamide 
    and BCG (FAC-BCG). The results were compared to those observed 
    in a group of 44 patients treated with FAC chemotherapy alone. 
    Although the overall response rates were similar (76% for 
    FAC-BCG and 73% for FAC), the duration of remission was of 9 
    months for FAC and 14 months for FAC-BCG (p = 0.04). 
    Similarly, survival or responding patients treated with 
    FAC-BCG was significantly longer (24 months) than that 
    observed in the chemotherapy alone treated group (15 months). 
    There was no difference in survival or duration on study for 
    non-responders. Response rates were not influenced by dominant 
    site of disease, menopausal status or disease-free interval. 
    The duration of remission and survival, however, were 
    significantly longer for patients with bone and soft tissue 
    involvement than for patients with visceral metastasis. 
    Similarly patients with 1 or 2 metastatic sites survived 
    significantly longer than those with more than 3 organ sites 
    involved (p = 0.02). This chemotherapeutic combination is 
    highly effective in inducing remissions. In addition, 
    nonspecific immunotherapy with BCG appears to prolong duration 
    of remission and survival for responding patients. 
advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application



 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.